-
Share
1,799 Posts.
322
15/09/21
21:03
Share
Just in case anyone thinks the conjunctivitis study conclusions were a one off, then read this study from August 21
www.mdpi.com/1999-4915/13/8/1656/htm
Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice
In it, Jeremy Paul et all conclude that:-
“The potential protective effects of astodrimer sodium 1% nasal spray warrant further investigation to help combat SARS-CoV-2 infection in humans.”
Not “immediate commercialisation”, but “further investigation ”.
How much more investigation? A month? A year?? Five years???
-
